| Embryonic origin | In many cases, ERMS occurs in regions without abundant or in some cases, regions without any detectable skeletal muscle. Therefore, the relationship of ERMS to skeletal muscle is not clear. However, it is postulated that ERMS is derived from mesenchymal precursors of mesodermal origin. |
| Epidemiology | ERMS accounts for 70-80% of all RMS tumors, and usually occurs in young children (median age of 6.5 years). ERMS represents ~4% of all malignancies among children and adolescents, and has an annual incidence of ~4 per million. |
| Clinics | ERMS often occurs in the head and neck region, genitourinary tract, and retroperitoneum. This tumor often presents as a painless mass, but in other cases, may be discovered from symptoms produced by compression of structures at the primary site. A small fraction of ERMS (10%) will have metastatic disease at the time of diagnosis, with the most frequent site of metastasis being the lungs. The standard treatment for ERMS is a combination of surgery, radiation, and intensive chemotherapy. |
| Pathology | The term embryonal RMS was coined to indicate the microcopic similarity of the tumor cells to developing skeletal myocytes. The tumors cells show variable myogenic differentiation, from small round cells to larger oblong cells with eosinophilic cytoplasm. In the most differentiated cells, there is a strap-like appearance, occasionally with cross striations and multinucleation. From an architectural standpoint, these tumors classically have variable cellularity, with hypercellular areas alternating with hypocellular areas containing a loose myxoid stroma.
Spindle cell RMS has dense whorls or bundles of spindle-shaped cells resembling smooth muscle. These tumors often occur in the paratesticular region of children and the head and neck region of adults. Botryoid RMS usually occurs in the lumen of a hollow internal organ, such as the urinary bladder or vagina. This form of RMS has the gross appearance of multiple polypoid nodules, and the microscopic appearance of a dense cambium layer of tumor cells under an intact epithelial surface.
Anaplasia is recognized by the presence of large, lobated hyperchromatic nuclei and atypical mitoses. Anaplastic cells can be found in a focal or diffuse distribution. |
| |  |
| |
| Histopathology of ERMS (hematoxylin-eosin, original magnification: 100X; courtesy of Dr. Linda Ernst). |
| |
| Prognosis | Patients with ERMS tumors have a better outcome than patients with ARMS tumors. The 4-year failure free survival rates for patients with localized and metastastic ARMS are 85% and 35%, respectively. Other risk factors that influence outcome of ERMS include age, primary site, size of primary tumor, extent of local spread, and the presence of nodal and distal metastases. Based on these other factors, patients with ERMS tumors with limited extent of disease or in a favorable site (orbit, superficial head and neck, biliary tree, vagina, and paratestis) have a 85-95% probability of long-term survival. It should be also noted that though metastastic disease is a poor prognostic sign, patients with metastatic ERMS under 10 years of age have a survival rate of 40-50%, thus far exceeding the survival rate for metastatic ARMS. |
| Germline mutations in HRAS proto-oncogene cause Costello syndrome. |
| Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, Tanaka Y, Filocamo M, Kato K, Suzuki Y, Kure S, Matsubara Y. |
| Nat Genet. 2005 Oct;37(10):1038-40. Epub 2005 Sep 18. |
| PMID 16170316 |
| |
| Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV. |
| Breneman JC, Lyden E, Pappo AS, Link MP, Anderson JR, Parham DM, Qualman SJ, Wharam MD, Donaldson SS, Maurer HM, Meyer WH, Baker KS, Paidas CN, Crist WM. |
| J Clin Oncol. 2003 Jan 1;21(1):78-84. |
| PMID 12506174 |
| |
| Genomic gains and losses are similar in genetic and histologic subsets of rhabdomyosarcoma, whereas amplification predominates in embryonal with anaplasia and alveolar subtypes. |
| Bridge JA, Liu J, Qualman SJ, Suijkerbuijk R, Wenger G, Zhang J, Wan X, Baker KS, Sorensen P, Barr FG. |
| Genes Chromosomes Cancer. 2002 Mar;33(3):310-21. |
| PMID 11807989 |
| |
| Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. |
| Crist WM, Anderson JR, Meza JL, Fryer C, Raney RB, Ruymann FB, Breneman J, Qualman SJ, Wiener E, Wharam M, Lobe T, Webber B, Maurer HM, Donaldson SS. |
| J Clin Oncol. 2001 Jun 15;19(12):3091-102. |
| PMID 11408506 |
| |
| Tumor predisposition in Costello syndrome. |
| Gripp KW. |
| Am J Med Genet C Semin Med Genet. 2005 Aug 15;137C(1):72-7. Review |
| PMID 16010679 |
| |
| Soft Tissue Sarcomas. |
| Gurney JG, Young JL, Roffers SD, Smith MA, Bunin GR. |
| In L. A. Ries, M. A. Smith, J. G. Gurney, M. Linet, T. Tamra, J. L. Young, and G. R. Bunin (ed.), Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. NIH Pub. No. 99-4649, Bethesda, MD. 1999; p. 111-124. |
| |
| Rhabdomyosarcoma complicating multiple neurofibromatosis. |
| McKeen EA, Bodurtha J, Meadows AT, Douglass EC, Mulvihill JJ. |
| J Pediatr. 1978 Dec;93(6):992-3. |
| PMID 102756 |
| |
| Rhabdomyosarcomas in adults and children: an update. |
| Parham DM, Ellison DA. |
| Arch Pathol Lab Med. 2006 Oct;130(10):1454-65. |
| PMID 17090187 |
| |
| Prevalence and clinical impact of anaplasia in childhood rhabdomyosarcoma : a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. |
| Qualman S, Lynch J, Bridge J, Parham D, Teot L, Meyer W, Pappo A. |
| Cancer. 2008 Dec 1;113(11):3242-7. |
| PMID 18985676 |
| |
| Chromosomal localization of the human rhabdomyosarcoma locus by mitotic recombination mapping. |
| Scrable HJ, Witte DP, Lampkin BC, Cavenee WK. |
| Nature. 1987 Oct 15-21;329(6140):645-7. |
| PMID 3657988 |
| |
| Myogenin and MyoD1 expression in paediatric rhabdomyosarcomas. |
| Sebire NJ, Malone M. |
| J Clin Pathol. 2003 Jun;56(6):412-6. Review |
| PMID 12783965 |
| |
| Neurofibromatosis in children with Rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma study IV. |
| Sung L, Anderson JR, Arndt C, Raney RB, Meyer WH, Pappo AS. |
| J Pediatr. 2004 May;144(5):666-8. |
| PMID 15127010 |
| |
| Allelotype of pediatric rhabdomyosarcoma. |
| Visser M, Sijmons C, Bras J, Arceci RJ, Godfried M, Valentijn LJ, Voute PA, Baas F. |
| Oncogene. 1997 Sep;15(11):1309-14. |
| PMID 9315099 |
| |
| Chromosomal analysis of sixteen human rhabdomyosarcomas. |
| Wang-Wuu S, Soukup S, Ballard E, Gotwals B, Lampkin B. |
| Cancer Res. 1988 Feb 15;48(4):983-7. |
| PMID 3338090 |
| |
| Gains, losses, and amplification of genomic material in rhabdomyosarcoma analyzed by comparative genomic hybridization. |
| Weber-Hall S, Anderson J, McManus A, Abe S, Nojima T, Pinkerton R, Pritchard-Jones K, Shipley J. |
| Cancer Res. 1996 Jul 15;56(14):3220-4. |
| PMID 8764111 |
| |
| Rhabdomyosarcoma and the undifferentiated sarcomas. |
| Wexler LH, Meyer WH, Helman LJ. |
| In P. A. Pizzo and D. G. Poplack (ed.), Principles and Practice of Pediatric Oncology, 2006. Fifth ed. Lippincott Williams & Wilkins, Philadelphia; p. 971-1001. |
| |
| Molecular pathogenesis of rhabdomyosarcoma. |
| Xia SJ, Pressey JG, Barr FG. |
| Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104. |
| PMID 12170781 |
| |
